SOM Biotech signs licensing agreement with the University of Minnesota SOM Biotech signs licensing agreement with the University of Minnesota Barcelona, Spain, 16 May 2022. SOM Biotech (“SOM” or the “Company”), a clinical-stage biopharmaceutical company with a...

SOM Biotech signs letter of intent with Megapharm to commercialize SOM3355 in Israel and the Palestinian Authority SOM Biotech signs letter of intent with Megapharm to commercialize SOM3355 in Israel and the Palestinian Authority Barcelona, Spain, 15 December 2021. SOM Biotech (“SOM” or the “Company”), a...

SOM Biotech granted Orphan Drug Designation by the FDA for SOM3355 SOM Biotech granted Orphan Drug Designation by the FDA for SOM3355 ~SOM3355 has potential to be an alternative to current VMAT2 inhibitors with a significantly improved side effect profile for the...

SOM Biotech presents positive Phase 2a data with SOM3355 at the 34th ECNP Congress 2021 SOM Biotech presents positive Phase 2a data with SOM3355 at the 34th ECNP Congress 2021 ~Data show SOM3355 reduces chorea in patients with Huntingdon’s Disease and has a good safety profile~ ...